RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
1.045
-0.025 (-2.34%)
Nov 21, 2024, 3:15 PM EST - Market open
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
36.53M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Outset Medical | 114.73M |
DIH Holding US | 72.41M |
Carisma Therapeutics | 20.27M |
BioLineRx | 17.05M |
Beyond Air | 2.34M |
Lumos Pharma | 2.21M |
Adagio Medical Holdings | 543.00K |
Incannex Healthcare | 86.00K |
RAPT News
- 10 days ago - Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
- 4 months ago - RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus - Seeking Alpha
- 6 months ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB) - Benzinga
- 6 months ago - RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity - Seeking Alpha
- 7 months ago - RAPT Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 8 months ago - RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients - GlobeNewsWire
- 8 months ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 9 months ago - RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire